CORT corcept.com Earnings growth forecast for next year
Corcept Therapeutics (CORT) relies on the high margins of mifepristone and outsourced production. The projected change in earnings per share for the coming year demonstrates the market consensus, where the 112.60 mark reflects the latest data. A reputation as an endocrinology innovator is complemented by a strong team of biochemists and experts in bringing orphan drugs to market, ensuring stable business development.
CORT (Corcept Therapeutics Inc.): analytical breakdowns and indicator data
- share price and consensus valuation forecast:
- market capitalization data:
- book capitalization indicators:
- debt and solvency information:
Total Debt to Capital Corcept Therapeutics|CORT - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Corcept Therapeutics Corp|CORT - Company Total Debt Obligations|Debt to Book Capitalization Ratio Corcept|CORT - Company Long-Term Liabilities|Company Short-Term Debts Corcept Therapeutics|Quick Liquidity corcept.com
- net income and valuation ratios data:
CORT - Company Net Income|Expected Profit Corcept Therapeutics|CORT - Company Value to Net Income|Forward P/E Multiple Corcept Therapeutics Inc.|CORT - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Corcept Therapeutics|CORT - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Corcept Therapeutics|CORT - Earnings per one share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months corcept.com|CORT - Net earnings per one share growth for the current year|Expected earnings per share growth for next year Corcept Therapeutics
- total revenue and sales volume data:
Initial company analysis:CORT, corcept.com
This indicator measures the market's weighted average expectation for earnings per share in the next period, determining the asset's fair value through future cash flows. By analyzing this chart of the EPS n+1 consensus forecast trend, an investor assesses the stability of Corcept Therapeutics (CORT), where patent protection for endocrine drugs guarantees predictable income and minimizes the risk of overpaying for the business.
Analysis of competing companies
ASND (Ascendis) - Earnings growth forecast for next year|Earnings growth forecast for next year Madrigal Pharmaceuticals|Earnings growth forecast for next year RYTM|Net earnings per share growth forecast for next year AKRO (Akero Therapeutics, Inc.)|Net earnings per share growth forecast for next year metsera.com MTSR|MoonLake Corp (MLTX) - Expected net earnings per share growth next year|CRNX - Net earnings per share growth forecast for next year|NAMS: Net earnings per share growth forecast for next year|SLNO: Earnings growth forecast for next year|FOLD - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year 89bio Pharma|Agios Corp (AGIO) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year structuretx.com (GPCR)|Expected earnings per share growth for next year mimedx.com MDXG|Net earnings per share growth forecast for next year Rezolute RZLT|Lexicon Pharmaceuticals, Inc. - Net earnings per share growth forecast for next year|MBX: Expected earnings per share growth for next year|Altimmune Corp - Projected earnings per share increase next year|Aardvark Therapeutics Inc (AARD) - Net earnings per share growth forecast for next year|Net earnings per one share growth forecast for next year Sagimet Biosciences SGMT|BIOA (bioagelabs.com) - Earnings growth forecast for next year|Expected earnings per share growth for next year Biomea Fusion (BMEA)|Earnings growth forecast for next year QNCX|Projected earnings per share increase next year GUTS|Earnings growth forecast for next year VTVT (vTv Therapeutics Inc.)|Expected earnings per share trend next year ATPC|Pluristem Therapeutics - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year synlogictx.com SYBX|LPCN: Earnings growth forecast for next year|Matinas BioPharma Holdings, Inc. - Expected earnings per share trend next year|SPRB (Spruce Biosciences Inc.) - Earnings growth forecast for next year|galecto.com (GLTO) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Carmell Therapeutics (CTCX)|LUMO (Lumos Pharma Inc) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year organovo.com ONVO|Radius Health (RDUS) - Expected net earnings per share growth next year
